Literature DB >> 25850342

Antimicrobial resistance surveillance of doripenem in China.

Yun Li1, Yuan Lv1, Feng Xue1, Bo Zheng1, Jian Liu1, Jia Zhang1.   

Abstract

To investigate the antibacterial resistance to doripenem in China and to understand the distribution trends of resistant bacteria. All the clinical isolates were collected from hospitals and the susceptibility tests were performed using the agar dilution method recommended by the Clinical Laboratory Standards Institute (CLSI) central laboratory. The susceptibility of the isolates to antimicrobial agents was determined using the CLSI (2014) or European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2013) guidelines. A total of 4047 pathogenic strains were isolated from 18 tertiary hospitals in 18 cities across China between July 2011 and June 2012. MIC results indicated that the vast majority of Enterobacteriaceae maintained high susceptibility to doripenem, with a lower resistance rate (1.9%) than that observed for other drugs tested. In the case of non-fermenting Gram-negative isolates, the resistance rate of Pseudomonas aeruginosa was 16.2%, which was less than that of imipenem and meropenem, and the Acinetobacter baumannii doripenem resistance rate was 67.4%. Doripenem also showed good in vitro activity against other the bacteria tested. This study suggests that the gradual increase in carbapenem nonsusceptible Enterobacteriaceae should be monitored carefully alongside the increasing multidrug-resistant and extensively drug-resistant A. baumannii.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25850342     DOI: 10.1038/ja.2015.25

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  7 in total

1.  In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.

Authors:  M Tsuji; Y Ishii; A Ohno; S Miyazaki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

2.  Comparative activity of carbapenem testing: the COMPACT study.

Authors:  Patrice Nordmann; Juan J Picazo; Reinier Mutters; Volkan Korten; Alvaro Quintana; Joerg M Laeuffer; Joyce Chen Hian Seak; Robert K Flamm; Ian Morrissey
Journal:  J Antimicrob Chemother       Date:  2011-03-08       Impact factor: 5.790

3.  Activities of doripenem (S-4661) against drug-resistant clinical pathogens.

Authors:  Ronald N Jones; Holly K Huynh; Douglas J Biedenbach
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

4.  In vitro activity of doripenem.

Authors:  Daniel Sahm
Journal:  Clin Infect Dis       Date:  2009-08-15       Impact factor: 9.079

5.  [Surveillance on drug resistance of gram-negative bacilli isolated from hospital acquired infections and community acquired infections (2000 - 2001)].

Authors:  Jia-tai Li; Yun Li; Jin Wang
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2003-06-25

6.  In vitro activity of doripenem against Acinetobacter baumannii clinical isolates.

Authors:  Sara Marti; Javier Sánchez-Céspedes; Verónica Alba; Jordi Vila
Journal:  Int J Antimicrob Agents       Date:  2008-11-01       Impact factor: 5.283

7.  In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units: nationwide data from the SMART Programme.

Authors:  S-S Jean; P-R Hsueh; W-S Lee; H-T Chang; M-Y Chou; I-S Chen; J-H Wang; C-F Lin; J-M Shyr; W-C Ko; J-J Wu; Y-C Liu; W-K Huang; L-J Teng; C-Y Liu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-01-27       Impact factor: 3.267

  7 in total
  6 in total

1.  Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa.

Authors:  Neang S Ly; Zackery P Bulman; Jürgen B Bulitta; Christopher Baron; Gauri G Rao; Patricia N Holden; Jian Li; Mark D Sutton; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

2.  Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa.

Authors:  Kazuhiro Oshima; Shigeki Nakamura; Naoki Iwanaga; Koji Takemoto; Taiga Miyazaki; Kastunori Yanagihara; Yoshitsugu Miyazaki; Hiroshi Mukae; Shigeru Kohno; Koichi Izumikawa
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

3.  Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations.

Authors:  Yu Wang; Xiaofen Liu; Kun Li; Yaxin Fan; Jicheng Yu; Hailan Wu; Yi Li; Xiaojie Wu; Beining Guo; Xin Li; Jiali Hu; Jufang Wu; Guoying Cao; Jing Zhang
Journal:  Antibiotics (Basel)       Date:  2022-07-16

4.  MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.

Authors:  Cédric Bretonnière; Adeline Maitte; Jocelyne Caillon; Gilles Potel; David Boutoille; Cédric Jacqueline; Christophe Guitton
Journal:  J Antibiot (Tokyo)       Date:  2016-03-30       Impact factor: 2.649

5.  Assessment of Doripenem, Meropenem, and Imipenem against Respiratory Isolates of Pseudomonas aeroginosa in a Tertiary Care Hospital of North India.

Authors:  Arti Negi; Mridu Anand; Avinash Singh; Awadhesh Kumar; Chinmoy Sahu; Kashi Nath Prasad
Journal:  Indian J Crit Care Med       Date:  2017-10

6.  Communicating the promise, risks, and ethics of large-scale, open space microbiome and metagenome research.

Authors:  Daria Shamarina; Iana Stoyantcheva; Christopher E Mason; Kyle Bibby; Eran Elhaik
Journal:  Microbiome       Date:  2017-10-04       Impact factor: 14.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.